Literature DB >> 11465627

Psychotogenic properties of benzodiazepine receptor inverse agonists.

M Sarter1, J P Bruno, G G Berntson.   

Abstract

The neurochemical, behavioral, and cognitive effects of the benzodiazepine receptor partial inverse agonist beta-carboline FG 7142 (FG), a drug traditionally described as exhibiting 'anxiogenic' effects, are proposed to model core components of present theories of the neuronal mechanisms of schizophrenia. FG activates the mesolimbic dopaminergic system and, via increases in dopaminergic activity in the nucleus accumbens, disinhibits corticopetal cholinergic projections. The latter effect of FG is hypothesized to mediate the hyperattentional impairments that contribute to the development of psychotic cognition. Furthermore, the FG-induced abnormal overprocessing of conditioned stimuli and contexts provides an explanation of the 'anxiogenic' effects of FG. The FG-induced increases in the activity of cortical cholinergic inputs and the FG-induced cognitive impairments in rats and monkeys were demonstrated to be attenuated by the administration of typical and atypical antipsychotic drugs. Compared to the classic psychotogenic drugs amphetamine and phencyclidine, the effects of FG serve as an alternative psychotogenic manipulation in research focusing on the cortical and cognitive aspects of current theories of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465627     DOI: 10.1007/s002130100756

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

1.  Anxiogenic, not psychotogenic, properties of the partial inverse benzodiazepine receptor agonist FG 7142 in man.

Authors:  R Horowski; R Dorrow
Journal:  Psychopharmacology (Berl)       Date:  2002-07       Impact factor: 4.530

2.  Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats.

Authors:  Judit Laszy; István Laszlovszky; István Gyertyán
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

3.  Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome.

Authors:  Verónica Vidal; Susana García-Cerro; Paula Martínez; Andrea Corrales; Sara Lantigua; Rebeca Vidal; Noemí Rueda; Laurence Ozmen; Maria-Clemencia Hernández; Carmen Martínez-Cué
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

4.  FG 7142: is this validated tool to study anxiety now forgotten?

Authors:  R Horowski
Journal:  J Neural Transm (Vienna)       Date:  2020-01-11       Impact factor: 3.575

5.  Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors.

Authors:  John R Atack; Peter H Hutson; Neil Collinson; George Marshall; Graham Bentley; Christopher Moyes; Susan M Cook; Ian Collins; Keith Wafford; Ruth M McKernan; Gerard R Dawson
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 6.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

7.  Functional neuroimaging and behavioral correlates of capacity decline in visual short-term memory after sleep deprivation.

Authors:  Michael W L Chee; Y M Lisa Chuah
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

8.  Pathophysiological aspects of diversity in neuronal inhibition: a new benzodiazepine pharmacology.

Authors:  Hanns Möhler
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

Review 9.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

10.  Validation of a high throughput screening assay to identify small molecules that target the eukaryotic replicative helicase.

Authors:  Jordan Sanders; Michael Castiglione; Tongying Shun; Laura L Vollmer; Mark E Schurdak; Andreas Vogt; Anthony Schwacha
Journal:  SLAS Discov       Date:  2022-01-08       Impact factor: 3.341

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.